4.8 Article

An intermediate-effect size variant in UMOD confers risk for chronic kidney disease

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.2114734119

Keywords

genetic architecture; uromodulin; Autosomal Dominant Tubulointerstitial Kidney Disease; rare disease; ER stress

Funding

  1. Postdoc MobilityStipendien of the Swiss National Science Foundation [P2ZHP3_195181, P500PB_206851]
  2. Kidney Research UK Grant [Paed_RP_001_20180925]
  3. Fonds National de la Recherche Luxembourg Grant [6903109]
  4. University Research Priority Program Integrative Human Physiology, Zurich Center for Integrative Human Physiology (ZIHP) of the University of Zurich
  5. Ministry of Health of the Czech Republic Grant [NU2107-00033]
  6. Royal College of Surgeons in Ireland Blackrock Clinic Strategic Academic Recruitment (StAR) Doctor of Medicine (MD)
  7. University of Zurich [Forschungskredit FK-14-035]
  8. Italian Ministry of Health [RF-2010-2319394, RF2016-02362623]
  9. German Research Foundation (DFG) [KO 3598/5-1]
  10. DFG [431984000 SFB 1453, 387509280]
  11. Kidney Research UK
  12. Northern Counties Kidney Research Fund
  13. European Union [860977]
  14. Swiss National Science Foundation's National Center of Competence in Research Kidney Control of Homeostasis program
  15. Swiss National Science Foundation [310030189044]
  16. University Research Priority Program Innovative Therapies in Rare Diseases [43879]
  17. Gebert-R_uf Foundation for research on ADTKD-UMOD
  18. European Reference Network for Rare Kidney Diseases [739532]
  19. Marie Curie Actions (MSCA) [860977] Funding Source: Marie Curie Actions (MSCA)
  20. Swiss National Science Foundation (SNF) [P500PB_206851] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

The identification of an intermediate-effect UMOD variant reveals its contribution to CKD and provides new insights into the genetic architecture of CKD.
The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD), while common low-impact variants strongly associate with kidney function and the risk of chronic kidney disease (CKD) in the general population. It is unknown whether intermediate-effect variants in UMOD contribute to CKD. Here, candidate intermediate-effect UMOD variants were identified using large-population and ADTKD cohorts. Biological and phenotypical effects were investigated using cell models, in silico simulations, patient samples, and international databases and biobanks. Eight UMOD missense variants reported in ADTKD are present in the Genome Aggregation Database (gnomAD), with minor allele frequency (MAF) ranging from 10(-5) to 10(-3). Among them, the missense variant p.Thr62Pro is detected in similar to 1/1,000 individuals of European ancestry, shows incomplete penetrance but a high genetic load in familial clusters of CKD, and is associated with kidney failure in the 100,000 Genomes Project (odds ratio [OR] = 3.99 [1.84 to 8.98]) and the UK Biobank (OR = 4.12 [1.32 to 12.85). Compared with canonical ADTKD mutations, the p.Thr62Pro carriers displayed reduced disease severity, with slower progression of CKD and an intermediate reduction of urinary uromodulin levels, in line with an intermediate trafficking defect in vitro and modest induction of endoplasmic reticulum (ER) stress. Identification of an intermediate-effect UMOD variant completes the spectrum of UMOD-associated kidney diseases and provides insights into the mechanisms of ADTKD and the genetic architecture of CKD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available